(3-Tert-butylpiperidin-1-yl)-phenylmethanone | 1000789-45-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-Tert-butylpiperidin-1-yl)-phenylmethanone
• CAS: 1000789-45-6
• 化学式: C₁₆H₂₃NO
• 分子量: 245.365
• InChiKey: VXHFDVWTPOHDHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  5,5-dimethyl-4-methylidene-N-phenylsulfanylhexan-1-amine 、 苯甲酰氯 在 偶氮二异丁腈 、 三正丁基氢锡 、 三乙胺 作用下， 以 苯 为溶剂， 以42%的产率得到(3-Tert-butylpiperidin-1-yl)-phenylmethanone
  参考文献：
  名称：

  5-Exo versus 6-Endo Cyclization of Primary Aminyl Radicals:  An Experimental and Theoretical Investigation

  摘要：

  The cyclization of neutral primary pent-4-enylaminyl radicals was investigated experimentally and theoretically. Unlike the corresponding secondary aminyl radicals, primary pent-4-enylaminyl radicals underwent efficient cyclization to afford the pyrrolidine and/or piperidine products in good to high yields. While the simple pent-4-enylaminyl radical gave predominately the 5-exo, cyclization product, 4-chloropent-4-enylarninyl radicals led to the formation of the corresponding 6-endo cyclization products in excellent regioselectivity. Theoretical calculations revealed that the 5-exo cyclization rate of primary aminyl radicals is about 3-4 orders of magnitude higher than that of secondary aminyl radicals.

  DOI：

  10.1021/jo7015967

文献信息

• RENIN INHIBITORS
  申请人：Kwok Lily

  公开号：US20100105665A1

  公开（公告）日：2010-04-29

  Compounds, pharmaceutical compositions, kits, article of manufacture, methods of using, and method of preparing of compounds having the formula of: wherein the variables are as defined herein.

  化合物、药物组合物、试剂盒、制造物品、使用方法和制备方法，具有以下式子的化合物：其中变量的定义如下。
• TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Babu Srinivasan

  公开号：US20110201593A1

  公开（公告）日：2011-08-18

  The invention provides novel compounds of formula I having the general formula: wherein R 1 , R 2 , R 3 , X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

  本发明提供了具有以下一般式的新化合物I： 其中R1、R2、R3、X和Y如本文所述。因此，这些化合物可以在药学上可接受的组合物中提供，并用于治疗免疫或过度增生性疾病。
• US8148367B2
  申请人：——

  公开号：US8148367B2

  公开（公告）日：2012-04-03
• US8461328B2
  申请人：——

  公开号：US8461328B2

  公开（公告）日：2013-06-11
• 5-<i>Exo</i> versus 6-<i>Endo</i> Cyclization of Primary Aminyl Radicals:  An Experimental and Theoretical Investigation
  作者：Feng Liu、Kun Liu、Xinting Yuan、Chaozhong Li

  DOI：10.1021/jo7015967

  日期：2007.12.1

  The cyclization of neutral primary pent-4-enylaminyl radicals was investigated experimentally and theoretically. Unlike the corresponding secondary aminyl radicals, primary pent-4-enylaminyl radicals underwent efficient cyclization to afford the pyrrolidine and/or piperidine products in good to high yields. While the simple pent-4-enylaminyl radical gave predominately the 5-exo, cyclization product, 4-chloropent-4-enylarninyl radicals led to the formation of the corresponding 6-endo cyclization products in excellent regioselectivity. Theoretical calculations revealed that the 5-exo cyclization rate of primary aminyl radicals is about 3-4 orders of magnitude higher than that of secondary aminyl radicals.